Meeting Manufacturing Challenges Tied to Extended-Release Injectables - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Meeting Manufacturing Challenges Tied to Extended-Release Injectables
Industry experts working with extended-release injectables discuss challenges and solutions to formulating and manufacturing these complex products.


Pharmaceutical Technology
Volume 36, Issue 5, pp. 40-47

Unit operations

PharmTech: Compared with a simple solution or lyophilized formulation, what additional unit operations are required for ER injectables and why?

(Herbert, Alkermes): Manufacture of ER injectables usually consists of a process to manufacture the ER injectable microspheres or crystals and then the more traditional process of filling into vials or syringes. The steps required to produce a polymer particulate-based ER injectable include: encapsulation, extraction of solvent from the particle, isolation of the particles—usually by filtration, drying of the particles to remove residual solvent and ensure physical stability of the particle, and filling of the particles and sealing in a sterile vial for storage prior to use. These steps are required in addition to compounding to avoid putting stability and drug-release characteristics at risk All steps must take place within a "sterile core" to ensure the product is in fact sterile, and each operation requires a sterile validation effort. The latter can be challenging when solid particles are being made and manipulated.

(Thiel and Loffredo, Hospira): The additional unit operations depend on the type of ER formulation. In the case of PLGA microparticle formulations, these have traditionally been prepared using a double-emulsion technique. Briefly, the active ingredient is dissolved in an aqueous solution, and this solution is filter-sterilized. Separately, the PLGA polymer is dissolved in a water-immiscible organic solvent, and this solution is also filter-sterilized. The two phases are then combined with high-shear mixing or homogenization to prepare a water-in-oil (W/O) emulsion. This primary emulsion is diluted into a larger volume of another, outer aqueous phase with high-shear mixing to form the secondary emulsion (W/O/W).

Then, there is a solvent-removal step to harden the newly-formed PLGA microspheres, and filtration (sieving) and rinsing steps to isolate PLGA microspheres of the desired size distribution while rinsing away everything else. Finally, the microspheres are dried (bulk lyophilization) and sterile powder filled. If this procedure is used, the additional unit operations compared with traditional parenteral manufacturing are the sterile emulsification, solvent removal, and particle-harvesting operations. Bulk drying and sterile powder filling are also specialized operations.

There are other methods for preparing PLGA microparticles (e.g., spray drying), that would have entirely different unit operations. For in-situ gel forming ER formulations, the manufacturing operations are more traditional, but may require specialized filling to handle viscous solutions.

Tipton (Evonik): Additional unit operations required are specific to the final dosage form. So for microspheres, commonly an emulsion step as well as a sieving and drying step are required. For liposomes, either an extrusion or homogenization step is added. If the product is a conjugate such as a PEGylated protein, an additional synthesis step is required. An implant will require a melt extrusion.

Although these unit operations may be complex and add cost to individual products, they are the necessary steps to obtain the ER as compared with the conventional dose. The additional manufacturing cost is more than made up in the additional benefit and value of the resulting ER product.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here